Table 1:
Analysis of 15 trials including 759 dogs treated with ciclosporin for canine atopic dermatitis
| Total | Fontaine and Olivry 2001 | Iwasaki and others 2002 | Olivry and others 2002a | Olivry and others 2002b | Steffan and others 2003 | Olivry and others 2003 | Burton and others 2004 | Bensignor and Guaguère 2004 | Steffan and others 2005 | Thelen and others 2006 | Carlotti and others 2009 | Nuttall and others 2012 | Kovalik and others 2011a* | Kovalik and others 2012 | Dip and others 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number (%) of dogs | 759 | 14 | 92 | 61 | 15 | 117 | 30 | 41 | 15 | 266 | 25 | 8 | 21 | 13 | 16 | 25 |
| Vomiting | 26% | 2 (14) | 10 (11) | 23 (38) | 1 (7) | 43 (37) | 6 (20) | 4 (10) | 5 (33) | 82 (31) | 0 | 0 | 6 (29) | 3 (23) | 2 (13) | 10 (40) |
| Soft stools/diarrhoea | 15% | 0 | 13 (14) | 21 (34) | 3 (20) | 6 (5) | 0 | 4 (10) | 0 | 53 (20) | 0 | 0 | 2 (10) | 2 (15) | 5 (31) | 5 (20) |
| Miscellaneous | 3% | 0 | 0 | 0 | 1 (7) | 10 (9) | 1 (3) | 0 | 0 | 0 | 10 (40) | 0 | 0 | 0 | 0 | 2 (8) |
| Loss of appetite | 2% | 0 | 1 (1) | 0 | 0 | 5 (4) | 0 | 0 | 0 | 8 (3) | 0 | 0 | 1 (5) | 0 | 0 | 0 |
| Nodules/cyst | 1% | 0 | 0 | 0 | 0 | 7 (6) | 0 | 0 | 0 | 3 (1) | 0 | 0 | 0 | 0 | 0 | 0 |
| Urinary tract infection | 1% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 (4) | 0 | 0 | 0 | 0 | 0 | 0 |
| Gingival hyperplasia | 1% | 0 | 0 | 0 | 0 | 3 (3) | 0 | 0 | 0 | 6 (2) | 0 | 0 | 0 | 0 | 0 | 0 |
| Lethargy/lameness | 1% | 0 | 0 | 0 | 1 (7) | 0 | 0 | 0 | 1 (7) | 6 (2) | 0 | 0 | 0 | 0 | 0 | 1 (4) |
| Reproductive | 1% | 0 | 0 | 0 | 0 | 7 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Papillomatosis | 1% | 0 | 0 | 0 | 1 (7) | 0 | 1 (3) | 0 | 0 | 4 (2) | 0 | 0 | 0 | 0 | 0 | 1 (4) |
| Lymphadenopathy | 0.8% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 (2) | 0 | 0 | 0 | 0 | 0 | 0 |
| Neurological | 0.8% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 (2) | 1 (4) | 0 | 0 | 0 | 0 | 1 (4) |
| Other urine abnormalities | 0.3% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (8) |
| Urticaria/angio-oedema | 0.3% | 0 | 0 | 0 | 1 (7) | 0 | 1 (3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ADR requiring cessation of therapy | 5% | 0 | 5 (5) | 0 | 2 (13) | 10 (9) | 5 (17) | 0 | 0 | 11 (4) | 3 (12) | 0 | 0 | 0 | 0 | 0 |
| Total | 59.2% | 14% | 31% | 72% | 68% | 79% | 46% | 20% | 40% | 73% | 56% | 0% | 44% | 38% | 44% | 88% |
* All the trials used 5 mg/kg ciclosporin as Atopica (Novartis Animal Health) except Kovalik and others 2011a, which used 5 mg/kg ciclosporin as Equoral oral solution (Teva Pharmaceuticals)
ADR Adverse drug reaction